List of Implants Companies in France - 9

"Innovative medicine for everyone, everywhere"​ Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia is specialized in diabetes and obesity. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : https://www.adocia.com/careers/adocia-careers/

Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders. Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain. By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS). The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.

CryoTherapeutics is a company that focuses on developing cryotherapy systems for the treatment of heart attacks in Europe and the USA.

FineHeartis a French medical device company focused on creatingtechnologies in the cardiovascular field. The FineHeartinvention, anI.C.O.M.S. (Implantable Cardiac Output Management System), is wirelessly powered, fully implantable mechanical circulatory support device that is able to optimize cardiac output while preserving the heart’s innate contractility.

Based near Bordeaux (FR), IMPLANET is an international company with a US subsidiary in Boston, funded by European institutional and private investors. IMPLANET focuses on spine and knee products. Its flagship product, the Jazz™ latest generation implant, is intended to improve the treatment of spinal disorders requiring spinal fusion surgery. Protected by 4 sets of international patents, Jazz™ has obtained 510(k) clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. Taking into account the evolution of the global healthcare system, the IMPLANET Marketing team identifies a portfolio of products and services based on a detailed analysis of socio-economic, regulatory, demographic and cultural specifications. The IMPLANET R&D team focuses on a scientifically and clinically proven implant design, using top quality materials tested to the highest prevailing standards, associated with simple and user-friendly instrumentation. Our various workgroups, composed of surgeons, experienced engineers and product managers work closely together to offer a range of implants with scientifically sound specifications and the highest quality to adequately respond to requirements of healthcare professionals. IMPLANET is able to provide the best of what science and experience have to offer, while ensuring to the stakeholders the best value for their products, their needs and demands.

PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a prominent European Venture Capital firm specializing in Life sciences. PK MED was created around a small team of passionate and experienced experts in pharmaceutical and medical sciences, drug delivery and biomaterials design. PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Our expertise spans across critical healthcare domains, focusing on drug delivery systems for rheumatology and enhancing cell-homing techniques to improve bone marrow transplantation outcomes. The company has developed a portfolio of early projects in indications with high unmet medical needs, starting with Gout flare, Osteoarthritis and Hemoglobinopathies.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

UroMems was founded in 2011 and focuses on designing, developing and commercializing active implantable medical devices. The company is based at the heart of the French Silicon Valley, in the Sophia Antipolis technopark, near Nice, France.

About us Since its creation in 1962, continuous technological and market research, implementation of latest technology at all levels, dedication to customer satisfaction and high quality and reliability standards are the key factors in Vygon's growth. Vygon's name has become synonymous with quality and reliability in the field of single-use medical and surgical products. Know-how Our industrial culture grew along with the company. We now have 11 factories worldwide, and we manufacture some 210 million medical devices every year. 9 of our factories are located in Europe, including 5 in France. We inspect the entire production line, from procurement of raw materials through to distribution logistics. We guarantee the traceability of our products and quality control. Every pack we deliver results from the know-how and commitment of multidisciplinary teams that work together and learn from each other - the driving force behind Vygon. Conceived and designed by our engineers and technicians and manufactured in one of our 11 plants, Vygon products meet ISO 13485 standards as well as the environmental ISO standard 14001. 60 years after its creation, our group now has the support of 26 subsidiaries and 11 production sites, including 8 in Europe. Thanks to the hard work of its 2,619 employees, Vygon manufactures nearly 210 million medical devices every year.